Work

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

Year: 2026

Type: article

Abstract: Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi-induced vascular toxicity is linked to redox-sensitive reactions that disrupt vascular tone, leading to hypertension and endothelial dysfunction, the role of the renal-vascular axis remains underexplored. This review seeks to clarify the contribution of the renal-vascular axis to VEGFi-related toxicity, focusing on key mechanisms such as endothelial dysfunction, activation of the renin-angiotensin-aldosterone system, oxidative stress and disrupted glomerular filtration. The renal-vascular axis is essential for regulating blood pressure and vascular tone, and its dysfunction may amplify VEGFi-induced cardiovascular injury. By exploring the interplay between renal and vascular systems in this context, we identify novel cardiovascular biomarkers and therapeutic targets that could help mitigate the vascular toxicity of VEGFi therapy. Understanding these mechanisms is crucial for enhancing the cardiovascular safety of cancer treatments and improving patient outcomes.

Source: British Journal of Pharmacology

DOI: 10.1111/bph.70378

Authors: Grace Whelan, Karla B. Neves

Institution: University of Strathclyde

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,780